Stock Region Penny Picks
Your Stock Region Penny Picks Watchlist for Tuesday, May 20, 2025.
Your Stock Region Penny Picks Watchlist for Tuesday, May 20, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is for informational purposes only and does not constitute financial advice. Always do your own research or consult with a financial advisor before making investment decisions.
$KTTA - Pasithea Therapeutics
Pasithea released preclinical data revealing that PAS-004 inhibits ETS2 signaling, a major player in inflammation. This could be a game-changer for inflammatory diseases like IBD, targeting large, addressable markets.
$EDBL - Edible Garden
Edible Garden launched Kick. Sports Nutrition on Amazon, expanding their reach into e-commerce. They’ve also teamed up with Pirawna to fast-track brand growth efforts.
$IXHL - Incannex Healthcare
Incannex cancelled 50.4% of their Series A Warrants, a strategic move to cut down potential future dilution. Shareholders might find this action reassuring as it strengthens the company’s structure.
$CING - Cingulate
Cingulate shared positive efficacy results from their Phase 3 pediatric study for CTx-1301, a treatment for ADHD.
$NRXS - NeurAxis
NeurAxis secured the first-ever FDA clearance for pediatric FAP/functional dyspepsia (FD) treatment, alongside its related nausea symptoms. A major regulatory milestone for the company.
$TNMG - TNL Mediagene
Benchmark initiated coverage for this stock with a speculative buy rating and a price target of $3.50. This new coverage could bring fresh investor attention.
$HOWL - Werewolf Therapeutics
Following a clinical trial, HonorHealth Research Institute announced a patient with advanced skin cancer is in remission for over a year after using Werewolf Therapeutics’ WTX-124 pro-drug. Encouraging news for immunotherapy innovation.
$CERO - Cellular Immunotherapy
CERO has been granted a U.S. patent for proprietary cellular immunotherapy compositions aimed at treating cancer. This highlights their growing intellectual property portfolio in oncology.
Disclaimer: The information included in this newsletter does not serve as an investment recommendation. Stock trading involves substantial risk, and past performance is not indicative of future results.
We are working endlessly to provide free insights on the stock market every day, and greatly appreciate those who are paid members supporting the development of the Stock Region mobile application. Stock Region offers daily stock and option signals, watchlists, earnings reports, technical and fundamental analysis reports, virtual meetings, learning opportunities, analyst upgrades and downgrades, catalyst reports, in-person events, and access to our private network of investors for paid members as an addition to being an early investor in Stock Region. We recommend all readers to urgently activate their membership before reaching full member capacity (500) to be eligible for the upcoming revenue distribution program. Memberships now available at https://stockregion.net